Danish 'meme stock' Orphazyme plunges after drug setback - Reuters

nomporkin.blogspot.com

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo

June 18 (Reuters) - Orphazyme (ORPHA.CO) slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate, sending shares in Denmark's first so-called meme stock tumbling 75% in early trading.

Shares in the biotech company, which is yet to have a drug approved or make money, have been on a roller-coaster recently - like other "meme stocks" influenced by chatter on social media - as investors took positions ahead of the U.S. Food and Drug Administration's (FDA) decision.

Orphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.

As a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.

"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies'," broker Nordnet wrote in a note to clients.

Orphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.

The company said the FDA in a letter had said additional qualitative and quantitative evidence was needed to show the drug's effectiveness.

"As representative for Orphazyme's shareholders and as a shareholder myself, I am extremely disappointed," deputy board chairman Bo Jesper Hansen said in a statement.

The drugmaker said it would remain in dialogue with the FDA and would continue to seek approval for the treatment in Europe.

($1 = 6.2456 Danish crowns)

Reporting by Boleslaw Lasocki in Gdansk, Editing by Sherry Jacob-Phillips

Our Standards: The Thomson Reuters Trust Principles.

Adblock test (Why?)